Rasmussen TA - Search Results

1

Rasmussen TA, Anderson JL, Wightman F, Lewin SR. Rasmussen TA, et al. Curr Opin HIV AIDS. 2017 Jan;12(1):96-104. doi: 10.1097/COH.0000000000000328. Curr Opin HIV AIDS. 2017. PMID: 27607592 Free PMC article. Review.

2

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

Rasmussen TA, Schmeltz Søgaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, Dinarello C, Østergaard L, Tolstrup M. Rasmussen TA, et al. Hum Vaccin Immunother. 2013 May;9(5):993-1001. doi: 10.4161/hv.23800. Epub 2013 Jan 31. Hum Vaccin Immunother. 2013. PMID: 23370291 Free PMC article.

3

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.

Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS. Rasmussen TA, et al. Hum Vaccin Immunother. 2013 Apr;9(4):790-9. doi: 10.4161/hv.23202. Epub 2013 Apr 1. Hum Vaccin Immunother. 2013. PMID: 23563519 Free PMC article. Review.

4

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.

Høgh Kølbæk Kjær AS, Brinkmann CR, Dinarello CA, Olesen R, Østergaard L, Søgaard OS, Tolstrup M, Rasmussen TA. Høgh Kølbæk Kjær AS, et al. Among authors: rasmussen ta. AIDS. 2015 Jun 19;29(10):1195-200. doi: 10.1097/QAD.0000000000000678. AIDS. 2015. PMID: 25870990 Clinical Trial.

5

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP. Pinkevych M, et al. Among authors: rasmussen ta. PLoS Pathog. 2015 Jul 2;11(7):e1005000. doi: 10.1371/journal.ppat.1005000. eCollection 2015 Jul. PLoS Pathog. 2015. PMID: 26133551 Free PMC article.

6

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. Rasmussen TA, et al. Lancet HIV. 2014 Oct;1(1):e13-21. doi: 10.1016/S2352-3018(14)70014-1. Epub 2014 Sep 15. Lancet HIV. 2014. PMID: 26423811

7

Reversal of Latency as Part of a Cure for HIV-1.

Rasmussen TA, Tolstrup M, Søgaard OS. Rasmussen TA, et al. Trends Microbiol. 2016 Feb;24(2):90-97. doi: 10.1016/j.tim.2015.11.003. Epub 2015 Dec 11. Trends Microbiol. 2016. PMID: 26690612 Review.

8

Ethics of ART interruption after stem-cell transplantation.

Sugarman J, Lewin SR, Henrich TJ, Rasmussen TA. Sugarman J, et al. Among authors: rasmussen ta. Lancet HIV. 2016 Jan;3(1):e8-10. doi: 10.1016/S2352-3018(15)00248-9. Lancet HIV. 2016. PMID: 26762996 No abstract available.

9

The potential role for romidepsin as a component in early HIV-1 curative efforts.

Gunst JD, Tolstrup M, Rasmussen TA, Søgaard OS. Gunst JD, et al. Among authors: rasmussen ta. Expert Rev Anti Infect Ther. 2016;14(5):447-50. doi: 10.1586/14787210.2016.1164031. Epub 2016 Mar 24. Expert Rev Anti Infect Ther. 2016. PMID: 26953620 No abstract available.

10

Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Rasmussen TA, Lewin SR. Rasmussen TA, et al. Curr Opin HIV AIDS. 2016 Jul;11(4):394-401. doi: 10.1097/COH.0000000000000279. Curr Opin HIV AIDS. 2016. PMID: 26974532 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page